Fetal fibronectin and adverse infant outcomes in a predominantly human immunodeficiency virus-infected African population: A randomized controlled trial

Obstetrics and Gynecology

Volumn 109, Issue 2 PART 1, 2007, Pages 392-401

  Goldenberg, Robert L ^a   Andrews, William W ^b   Hoffman, Irving ^b   Fawzi, Wafai ^b   Valentine, Megan ^b   Young, Alicia ^b   Read, Jennifer S ^b   Brown, Elizabeth R ^b   Mudenda, Victor ^b   Kafulafula, George ^b   Mwinga, Kasonde ^b   Taha, Taha E ^b  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPICILLIN; ANTIBIOTIC AGENT; ERYTHROMYCIN; FIBRONECTIN; METRONIDAZOLE; PLACEBO;

ADULT; ADVERSE OUTCOME; AFRICA; ANTIBIOTIC THERAPY; ARTICLE; BIOASSAY; CHORIOAMNIONITIS; CLINICAL INDICATOR; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; DELIVERY; DISEASE ASSOCIATION; DISEASE COURSE; EVALUATION; FEMALE; FETUS; FETUS OUTCOME; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRAPARTUM CARE; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; NEWBORN; POPULATION STRUCTURE; PREGNANCY OUTCOME; PREMATURITY; PRENATAL CARE; PRIORITY JOURNAL; RISK REDUCTION; SAMPLE; SECOND TRIMESTER PREGNANCY; VAGINA DISCHARGE; VERTICAL TRANSMISSION;

ADULT; AFRICA SOUTH OF THE SAHARA; AFRICAN CONTINENTAL ANCESTRY GROUP; ANTI-BACTERIAL AGENTS; DISEASE TRANSMISSION, VERTICAL; FEMALE; FETAL PROTEINS; FIBRONECTINS; HIV INFECTIONS; HUMANS; PLACENTA; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS; PREMATURE BIRTH; VAGINA;

EID: 33846660157     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.AOG.0000247628.68415.00     Document Type: Article

References (22)

1. Sadovsky Y, Friedman SA. Fetal fibronectin and preterm labor [letter]. N Engl J Med 1992;326: 709.
2. Lockwood CJ, Senyei AE, Dische MR, Casal D, Shah KD, Thung SN, et al. Fetal fibronectin in cervical and vaginal secretions as a predictor of preterm delivery. N Engl J Med 1991;325:669-74.
3. Lockwood CJ, Wein R, Lapinski R, Casal D, Berkowitz G, Alvarez M, et al. The presence of cervical and vaginal fetal fibronectin predicts preterm delivery in an inner-city obstetric population. Am J Obstet Gynecol 1993;169:798-804.
4. Goldenberg RL, Mercer BM, Meis PJ, Copper RL, Das A, McNellis D. The preterm prediction study: fetal fibronectin testing and spontaneous preterm birth. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol 1996;87:643-8.
5. Goldenberg RL, Klebanoff M, Carey JC, MacPherson C, Leveno KJ, Moawad AH, et al. Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth. Am J Obstet Gynecol 2000;183:469-75.
6. Lu GC, Goldenberg RL, Cliver SP, Kreaden US, Andrews WW. Vaginal fetal fibronectin levels and spontaneous preterm birth in symptomatic women. Obstet Gynecol 2001;97:225-8.
7. Goepfert AR, Goldenberg RL, Mercer B, Iams J, Meis P, Moawad A, et al. The preterm prediction study: quantitative fetal fibronectin values and the prediction of spontaneous preterm birth. The National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 2000;183:1480-3.
8. Goldenberg RL, Mercer BM, Iams JD, Moawad AH, Meis PJ, Das A, et al. The preterm prediction study: patterns of cervicovaginal fetal fibronectin as predictors of spontaneous preterm delivery. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. Am J Obstet Gynecol 1997;177:8-12.
9. Revah A, Hannah ME, Sue-A-Quan AK. Fetal fibronectin as a predictor of preterm birth: an overview. Am J Perinatol 1998;15:613-21.
10. Nageotte MP, Casal D, Senyei AE. Fetal fibronectin in patients at increased risk for premature birth. Am J Obstet Gynecol 1994;170:20-5.
11. Goldenberg RL, Iams JD, Mercer BM, Meis PJ, Moawad AH, Copper RL, et al. The Preterm Prediction Study: the value of new vs standard risk factors in predicting early and all spontaneous preterm births. NICHD MFMU Network. Am J Public Health 1998;88:233-8.
12. Peaceman AM, Andrews WW, Thorp JM, Cliver SP, Lukes A, Iams JD, et al. Fetal fibronectin as a predictor of preterm birth in patients with symptoms: a multicenter trial. Am J Obstet Gynecol 1997;177:13-8.
13. Iams JD, Casal D, McGregor JA, Goodwin TM, Kreaden US, Lowensohn R, et al. Fetal fibronectin improves the accuracy of diagnosis of preterm labor. Am J Obstet Gynecol 1995;173:141-5.
14. Goldenberg RL, Mwatha A, Read J, Adeniyi-Jones S, Sinkala M, Msmanga G, et al. The HPTN 024 Study: the efficacy of antibiotics to prevent chorioamnionitis and preterm birth. Am J Obstet Gynecol 2006;194:650-61.
15. Taha TE, Brown ER, Hoffman IF, Fawzi W, Read JS, Sinkala M, et al. A phase III clinical trial of antibiotics to reduce chorioamnionitis-related perinatal HIV-1 transmission. AIDS 2006;20:1313-21.
16. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991;29:297-301.
17. Goldenberg RL, Mudenda V, Read JS, Brown ER, Sinkala M, Kamiza S, et al. HPTN 024 study: histologic chorioamnionitis, antibiotics and adverse infant outcomes in a predominantly HIV-infected African population. Am J Obstet Gynecol 2006;195:1065-74.
18. Little RJ, Rubin DB. Statistical analysis with missing data. 2nd ed. Hoboken (NJ): John Wiley and Sons; 2000. p. 278-81.
19. Goldenberg RL, Thom E, Moawad AH, Johnson F, Roberts J, Caritis SN. The preterm prediction study: fetal fibronectin, bacterial vaginosis, and peripartum infection. NICHD Maternal Fetal Medicine Units Network. Obstet Gynecol 1996;87:656-60.
20. Goldenberg RL, Hauth JC, Andrews WW. Intrauterine infection and preterm delivery. N Engl J Med 2000;342:1500-7.
21. Yoon BH, Romero R, Moon JB, Oh SY, Han SY, Kim JC, et al. The frequency and clinical significance of intra-amniotic inflammation in patients with a positive cervical fetal fibronectin. Am J Obstet Gynecol 2001;185:1137-42.
22. Pastore LM, Royce RA, Jackson TP, Thorp JM Jr, Savitz DA, Kreaden US. Association between bacterial vaginosis and fetal fibronectin at 24-29 weeks' gestation. Obstet Gynecol 1999;93:117-23.